Parkinson's disease and the gut: A well known clinical association in need of an effective cure and explanation

Neurogastroenterology and Motility

Volumn 20, Issue 7, 2008, Pages 741-749

  Natale, G ^a   Pasquali, L ^a   Ruggieri, S ^b   Paparelli, A ^a   Fornai, F ^a,b  

^a UNIVERSITY OF PISA   (Italy)

^b IRCCS NEUROMED   (Italy)

Author keywords

Autonomic nervous system; Digestive tract; Dopamine; Noradrenaline; Parkinson's disease

Indexed keywords

4 AMINOBUTYRIC ACID; ACETYLCHOLINE; ALPHA SYNUCLEIN; APOMORPHINE; BENZATROPINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CISAPRIDE; DOMPERIDONE; DOPAMINE; LEVODOPA; METOCLOPRAMIDE; NORADRENALIN; SEROTONIN; TRIHEXYPHENIDYL;

BLURRED VISION; CARDIOTOXICITY; CLINICAL FEATURE; CONFUSION; CONSTIPATION; DIGESTIVE SYSTEM; DOPAMINERGIC NERVE CELL; GASTROINTESTINAL MOTILITY; GASTROINTESTINAL TRACT; HALLUCINATION; HUMAN; INTESTINE MOTILITY; LEWY BODY; MEMORY DISORDER; MUCOSAL DRYNESS; NERVE CELL NETWORK; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW; STOMACH EMPTYING; URINE RETENTION;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANIMALS; CENTRAL NERVOUS SYSTEM; DISEASE MODELS, ANIMAL; DOPAMINE; DOPAMINE AGENTS; DOPAMINE ANTAGONISTS; GASTROINTESTINAL DISEASES; GASTROINTESTINAL MOTILITY; GASTROINTESTINAL TRACT; HUMANS; LEWY BODIES; NEUROTRANSMITTER AGENTS; PARKINSON DISEASE;

EID: 44949159626     PISSN: 13501925     EISSN: 13652982     Source Type: Journal    
DOI: 10.1111/j.1365-2982.2008.01162.x     Document Type: Review

References (49)

1. Edwards LL, Quigley EM, Harned RK, Hofman R, Pfeiffer RF. Characterization of swallowing and defecation in Parkinson's disease. Am J Gastroenterol 1994 89 : 15 25.
2. Pfeiffer RF. Gastrointestinal dysfunction in Parkinson's disease. Lancet Neurol 2003 2 : 107 16.
3. Verbaan D, Marinus J, Visser M, van Rooden SM, Stiggelbout AM, van Hilten JJ. Patient reported autonomic symptoms in Parkinson disease. Neurology 2007 69 : 333 41.
4. Anderson G, Noorian AR, Taylor G et al. Loss of enteric dopaminergic neurons and associated changes in colon motility in an MPTP mouse model of Parkinson's disease. Exp Neurol 2007 207 : 4 12.
5. Eaker EY, Bixler GB, Dunn AJ, Moreshead WV, Mathias JR. Chronic alterations in jejunal myoelectric activity in rats due to MPTP. Am J Physiol 1987 253 : 809 15.
6. Singaram C, Ashraf W, Gaumnitz EA et al. Dopaminergic defect of enteric nervous system in Parkinson's disease patients with chronic constipation. Lancet 1995 346 : 861 4.
7. Wakabayashi K, Takahashi H, Takeda S, Ohama E, Ikuta F. The presence of Lewy bodies in Auerbach's and Meissner's plexuses. Acta Neuropathol 1988 76 : 217 21.
8. Fornai F, Di Poggio AB, Pellegrini A, Ruggieri S, Paparelli A. Noradrenaline in Parkinson's disease: from disease progression to current therapeutics. Curr Med Chem 2007 14 : 2330 4.
9. Forno LS, Langston JW, DeLanney LE, Irwin I, Ricaurte GA. Locus coeruleus lesions and eosinophilic inclusions in MPTP-treated monkeys. Ann Neurol 1986 20 : 449 55.
10. Pollanen MS, Dickson DW, Bergeron CB. Pathology and biology of the Lewy body. J Neuropathol Exp Neurol 1993 52 : 183 91.
11. Zweig RM, Jankel WR, Herdreen JC, Mayeux R, Price DL. The pedunculopontine nucleus in Parkinson's disease. Ann Neurol 1989 26 : 41 6.
12. Okazaki H, Lipkin LE, Aronson SM. Diffuse intracytoplasmic ganglionic inclusions (Lewy type) associated with progressive dementia and quadriparesis in flexion. J Neuropathol Exp Neurol 1961 20 : 237 44.
13. Fornai F, Soldani P, Lazzeri G et al. Neuronal inclusions in degenerative disorders Do they represent static features or a key to understand the dynamics of the disease? Brain Res Bull 2005 65 : 275 90.
14. Lee SS, Kim YM, Junn E et al. Cell cycle aberrations by alpha-synuclein over-expression and cyclin B immunoreactivity in Lewy bodies. Neurobiol Aging 2003 24 : 687 96.
15. Kupsky WJ, Grimes MM, Sweeting J, Bertsch R, Cote LJ. Parkinson's disease and megacolon: concentric hyaline inclusions (Lewy bodies) in enteric ganglion cells. Neurology 1987 37 : 1253 5.
16. Wakabayashi K, Takahashi H, Ohama E, Takeda S, Ikuta F. Lewy bodies in the visceral autonomic nervous system in Parkinson's disease. Adv Neurol 1993 60 : 609 12.
17. Phillips RJ, Walter GC, Wilder SL, Baronowsky EA, Powley TL. Alpha-synuclein-immunopositive myenteric neurons and vagal preganglionic terminals: Autonomic pathways implicated in Parkinson's disease? Neuroscience 2008 153 : 733 50. doi :.
18. Del Tredici K, Rüb U, De Vos RA, Bohl JR, Braak H. Where does Parkinson disease pathology begin in the brain? J Neuropathol Exp Neurol 2002 61 : 413 26.
19. Tong J, Hornykiewicz O, Kish SJ. Inverse relationship between brain noradrenaline level and dopamine loss in Parkinson disease: a possible neuroprotective role for noradrenaline. Arch Neurol 2006 63 : 1724 8.
20. Sasaki M, Shibata E, Tohyama K et al. Neuromelanin magnetic resonance imaging of locus coeruleus and substantia nigra in Parkinson's disease. Neuroreport 2006 17 : 1215 8.
21. Mavridis M, Degryse AD, Lategan AJ, Marien MR, Colpaert FC. Effects of locus coeruleus lesions on parkinsonian signs, striatal dopamine and substantia nigra cell loss after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in monkeys: a possible role for the locus coeruleus in the progression of Parkinson's disease. Neuroscience 1991 41 : 507 23.
22. Gesi M, Soldani P, Giorgi FS, Santinami A, Bonaccorsi I, Fornai F. The role of the locus coeruleus in the development of Parkinson's disease. Neurosci Biobehav Rev 2000 24 : 655 68.
23. Rye D, DeLong MR. Time to focus on the locus. Arch Neurol 2003 60 : 320.
24. Rommelfanger KS, Weinshenker D. Norepinephrine: The redheaded stepchild of Parkinson's disease. Biochem Pharmacol 2007 74 : 177 90.
25. Chaudhuri KR, Martinez-Martin P, Schapira AH et al. International multicenter pilot study of the first comprehensive self-completed nonmotor symptoms questionnaire for Parkinson's disease: the NMSQuest study. Mov Disord 2006 21 : 916 23.
26. Fornai F, Ruffoli R, Soldani P, Ruggieri S, Paparelli A. The "Parkinsonian heart": from novel vistas to advanced therapeutic approaches in Parkinson's disease. Curr Med Chem 2007 14 : 2421 8.
27. Parkinson J. An Essay on the Shaking Palsy. London : Whittingham and Rowland, 1817.
28. Hardoff R, Sula M, Tamir A et al. Gastric emptying time and gastric motility in patients with Parkinson's disease. Mov Disord 2001 16 : 1041 7.
29. Hagenmüller F, Classen M. Motility of Oddi's sphincter in Parkinson's disease, progressive systemic sclerosis, and achalasia. Endoscopy 1988 20 : 189 92.
30. Chaudhuri KR, Yates L, Martinez-Martin P. The non-motor symptom complex of Parkinson's disease: a comprehensive assessment is essential. Curr Neurol Neurosci Rep 2005 5 : 275 83.
31. Byrne KG, Pfeiffer R, Quigley EM. Gastrointestinal dysfunction in Parkinson's disease. A report of clinical experience at a single center. J Clin Gastroenterol 1994 19 : 11 6.
32. Jost WH, Schrank B. Defecatory disorders in de novo Parkinsonians-colonic transit and electromyogram of the external anal sphincter. Wien Klin Wochenschr 1998 110 : 535 7.
33. Hasler WL. Small intestinal motility. In : Johnson LR, ed. Physiology of the Gastrointestinal Tract. 4th edn. San Diego, CA : Elsevier 2006 : 935 64.
34. Gibbons SJ, Farrugia G. The role of carbon monoxide in the gastrointestinal tract. J Physiol 2004 556 : 325 36.
35. Li ZS, Pham TD, Tamir H, Chen JJ, Gershon MD. Enteric dopaminergic neurons: definition, developmental lineage, and effects of extrinsic denervation. J Neurosci 2004 24 : 1330 9.
36. Vaughan CJ, Aherne AM, Lane E, Power O, Carey RM, O'Connell DP. Identification and regional distribution of the dopamine D(1A) receptor in the gastrointestinal tract. Am J Physiol Regul Integr Comp Physiol 2000 279 : 599 609.
37. Minguez-Castellanos A, Chamorro CE, Escamilla-Sevilla F et al. Do alpha-synuclein aggregates in autonomic plexuses predate Lewy body disorders?: a cohort study. Neurology 2007 68 : 2012 8.
38. Kaufmann H, Nahm K, Purohit D, Wolfe D. Autonomic failure as the initial presentation of Parkinson disease and dementia with Lewy bodies. Neurology 2004 63 : 1093 5.
39. Li ZS, Schmauss C, Cuenca A, Ratcliffe E, Gershon MD. Physiological modulation of intestinal motility by enteric dopaminergic neurons and the D2 receptor: analysis of dopamine receptor expression, location, development, and function in wild-type and knock-out mice. J Neurosci 2006 26 : 2798 807.
40. Walker JK, Gainetdinov RR, Mangel AW, Caron MG, Shetzline MA. Mice lacking the dopamine transporter display altered regulation of distal colonic motility. Am J Physiol Gastrointest Liver Physiol 2000 279 : G311 8.
41. Szabo S, Brown A, Pihan G, Dali H, Neumeyer JL. Duodenal ulcer induced by MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropiridine). Proc Soc Exp Biol Med 1985 180 : 567 71.
42. Giovanni A, Sieber BA, Heikkila RE, Sonsalla PK. Studies on species sensitivity to the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine. Part 1: Systemic administration. J Pharmacol Exp Ther 1994 270 : 1000 7.
43. Giovanni A, Sonsalla PK, Heikkila RE. Studies on species sensitivity to the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Part 2: Central administration of 1-methyl-4-phenylpyridinium. J Pharmacol Exp Ther 1994 270 : 1008 14.
44. Hanani M. Rapid effects of MPTP in the mouse colon. Eur J Pharmacol 1990 175 : 273 7.
45. Mathers SE, Kempster PA, Law P et al. Anal sphincter dysfunction in Parkinson's disease. Arch Neurol 1989 46 : 1061 4.
46. Morgan JC, Sethi KD. Tegaserod in constipation associated with Parkinson disease. Clin Neuropharmacol 2007 30 : 52 4.
47. De Keyser J, De Backer JP, Wilczak N, Herroelen L. Dopamine agonists used in the treatment of Parkinson's disease and their selectivity for the D1, D2, and D3 dopamine receptors in human striatum. Prog Neuropsychopharmacol Biol Psychiatry 1995 19 : 1147 54.
48. Mouradian MM. Should levodopa be infused into the duodenum? Neurology 2005 64 : 216 23.
49. Tourtellotte WW, Syndulko K, Potvin AR, Hirsch SB, Potvin JH. Increased ratio of carbidopa to levodopa in treatment of Parkinson's disease. Arch Neurol 1980 37 : 723 6.